You are here
Vertex Announces Retirement of Peter Mueller, Ph.D.
"Peter is a visionary who embodied Vertex's fearless pursuit of
transformational medicines," said
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases.
Founded in 1989 in
Vertex's press releases are available at www.vrtx.com.
Special Note Regarding Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, including, without
limitation, the statements in the third paragraph of this press release.
While Vertex believes the forward-looking statements contained in this
press release are accurate, there are a number of factors that could
cause actual events or results to differ materially from those indicated
by such forward-looking statements. Those risks and uncertainties
include, among other things, the risks listed under Risk Factors in
Vertex's annual report and quarterly reports filed with the
News Provided by Acquire Media